- |||||||||| Fycompa (perampanel) / Eisai, carbamazepine / Generic mfg.
Use of Perampanel Without Therapeutic Drug Monitoring (Hall E) - Nov 28, 2019 - Abstract #AES2019AES_284;
Perampanel is metabolized by the CYP3A4&5 system, and use of ASDs that are inducers this system can significantly reduce perampanel concentrations.1 Thus, the prediction of the appropriate dose is difficult and lack of the ability to use therapeutic drug monitoring to guide treatment may lengthen the duration of trial and error seen in this study. In the subject eventually needing 22 mg/day, the dose escalation may have been done more rapidly if it were known that the levels produced by the usual perampanel doses were low.
- |||||||||| tacrolimus / Generic mfg., methylprednisolone / Generic mfg., carbamazepine / Generic mfg.
Efficacy of Intensive Treatment for Intractable Seizures in a Case of Adult-Onset Rasmussen Syndrome (Hall E) - Nov 28, 2019 - Abstract #AES2019AES_281;
We challenged cessation of ZNS, dose increase of CBZ and LTG, and addition of clobazam...Conclustions This case highlights the importance of intensive treatment including oral corticosteroid, T-cell inactivating drugs, IVIG, IVMP, VNS, and AEDs for seizure reduction in therapy of patients with adult-onset RS. Especially, in addition to basic immunotherapy, VNS along with the best-adjusted AEDs should be considered in progressive cases.
- |||||||||| Enrollment change, Trial termination, Trial primary completion date, Adverse events: Pharmacovigilance in Gerontopsychiatric Patients (clinicaltrials.gov) - Oct 19, 2017
P3, N=407, Terminated,
Especially, in addition to basic immunotherapy, VNS along with the best-adjusted AEDs should be considered in progressive cases. N=2000 --> 407 | Recruiting --> Terminated | Trial primary completion date: Feb 2017 --> Jun 2017
- |||||||||| lamotrigine liquid oral suspension / OWP Pharma
Trial completion, Enrollment change, Trial primary completion date: EDIPP: Early Detection and Intervention for the Prevention of Psychosis (clinicaltrials.gov) - Oct 23, 2015
P=N/A, N=3337, Completed,
N=2000 --> 407 | Recruiting --> Terminated | Trial primary completion date: Feb 2017 --> Jun 2017 Active, not recruiting --> Completed | N=350 --> 3337 | Trial primary completion date: May 2012 --> May 2013
- |||||||||| lamotrigine liquid oral suspension / OWP Pharma, NN1213 / Novo Nordisk
Trial completion: Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=5000, Completed,
Active, not recruiting --> Completed | N=350 --> 3337 | Trial primary completion date: May 2012 --> May 2013 No longer recruiting --> Completed
|
